Background: Hepatocellular carcinoma (HCC) is a common cause of worldwide mortality.
INTRODUCTION

OVERVIEW OF HEPATOCELLULAR CARCINOMA
Synopsis
Hepatic cancer is the fifth most frequently diagnosed cancer in men and seventh in women worldwide, HCC being the most common. Incidence rates of HCC are increasing across the globe as a result of intravenous drug abuse, hepatitis C virus (HCV) infection, and nonalcoholic steatohepatitis (NASH) [1] . The incidence of HCC in the USA is approximately 3 per 100,000 persons, with significant gender, ethnic, and geographic variations. Approximately 22,000 new cases and 18,000 deaths occur in the USA yearly [2] . Abdominal bruits are noted in 6-25%. Splenomegaly is a common finding, mainly due to portal hypertension. 
Current Management
The BCLC system is currently the most commonly used staging system to guide the management of HCC (Fig. 1) 
Administration
Once a patient is deemed eligible, TARE is performed on an outpatient basis either on a different day or in the same session [21] . Selective catheterization of the vessel chosen by pretreatment angiography is performed.
For glass microspheres, the final total dose administered is calculated by using the inverse of the dose formula:
However, this formula needs to be corrected for two post-treatment confounding factors: residual activity (R) not fully administered and lung shunt fraction (LSF):
For resin microspheres, the administered activity depends on percentage of the liver involved by the tumor. Greater than 50% requires 3.0 GBq, 25-50% requires 2.5 GBq, and less than 25% requires 2.0 GBq. The dose is reduced depending on the degree of lung shunting as calculated by the LSF. LSF less than 10% requires no dose reduction. LSF between 10% and 15% requires a 20% dose reduction.
LSF between 15% and 20% requires a 40% dose reduction. LSF greater than 20% cannot be treated [23] .
Post-Treatment Assessment
The tumor response of patients treated with Kulik et al. showed that TARE alone was just as effective as TARE combined with sorafenib, although the latter group experienced more biliary complications necessitating reduced sorafenib dose [51] .
Cost-effectiveness
Cost analyses investigating the intra-arterial therapies for HCC have been performed. TACE was estimated at US$17,000; unilobar and bilobar TARE reached US$31,000 and US$48,000, respectively. The incremental cost-effectiveness ratio in the BCLC C subgroup favored TARE by US$360 per month. Cost-effectiveness was incomparable in the BCLC B group [52] . Another similar simulated analysis showed that Y90 was less expensive than TACE one-third of the time, although this depends on the need for repeat procedures. Though meticulous, this and other studies did not factor improvement in QoL, days lost from work after treatment, hospital length-of-stay, a higher average number of TACE sessions per patient compared to TARE, and other ancillary costs [53] . 
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